Donepezil Hydrochloride; Memantine Hydrochloride Patent Expiration

Donepezil Hydrochloride; Memantine Hydrochloride is Used for managing moderate to severe dementia in Alzheimer's disease. It was first introduced by Abbvie Inc in its drug Namzaric on Dec 23, 2014. 3 different companies have introduced drugs containing Donepezil Hydrochloride; Memantine Hydrochloride.


Donepezil Hydrochloride; Memantine Hydrochloride Patents

Given below is the list of patents protecting Donepezil Hydrochloride; Memantine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Namzaric US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia Apr 11, 2015

(Expired)

Abbvie
Namzaric US5061703

(Pediatric)

Adamantane derivatives in the prevention and treatment of cerebral ischemia Oct 11, 2015

(Expired)

Abbvie
Namzaric US8039009 Modified release formulations of memantine oral dosage forms Mar 24, 2029 Abbvie
Namzaric US8039009

(Pediatric)

Modified release formulations of memantine oral dosage forms Sep 24, 2029 Abbvie
Namzaric US8058291 Methods and compositions for the treatment of CNS-related conditions Dec 05, 2029 Abbvie
Namzaric US8168209 Method and composition for administering an NMDA receptor antagonist to a subject Nov 22, 2025 Abbvie
Namzaric US8168209

(Pediatric)

Method and composition for administering an NMDA receptor antagonist to a subject May 22, 2026 Abbvie
Namzaric US8173708 Method and composition for administering an NMDA receptor antagonist to a subject Nov 22, 2025 Abbvie
Namzaric US8173708

(Pediatric)

Method and composition for administering an NMDA receptor antagonist to a subject May 22, 2026 Abbvie
Namzaric US8283379 Methods and compositions for the treatment of CNS-related conditions Nov 22, 2025 Abbvie
Namzaric US8283379

(Pediatric)

Methods and compositions for the treatment of CNS-related conditions May 22, 2026 Abbvie
Namzaric US8293794 Methods and compositions for the treatment of CNS-related conditions Nov 22, 2025 Abbvie
Namzaric US8329752 Composition for administering an NMDA receptor antagonist to a subject Nov 22, 2025 Abbvie
Namzaric US8329752

(Pediatric)

Composition for administering an NMDA receptor antagonist to a subject May 22, 2026 Abbvie
Namzaric US8338485 Compositions for the treatment of CNS-related conditions Nov 22, 2025 Abbvie
Namzaric US8338486 Methods for the treatment of CNS-related conditions Nov 22, 2025 Abbvie
Namzaric US8362085 Method for administering an NMDA receptor antagonist to a subject Nov 22, 2025 Abbvie
Namzaric US8362085

(Pediatric)

Method for administering an NMDA receptor antagonist to a subject May 22, 2026 Abbvie
Namzaric US8580858 Compositions for the treatment of CNS-related conditions Nov 22, 2025 Abbvie
Namzaric US8598233 Method for administering an NMDA receptor antagonist to a subject Nov 22, 2025 Abbvie
Namzaric US8598233

(Pediatric)

Method for administering an NMDA receptor antagonist to a subject May 22, 2026 Abbvie


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳

Donepezil Hydrochloride; Memantine Hydrochloride Generics

Several generic applications have been filed for Donepezil Hydrochloride; Memantine Hydrochloride. The first generic version for Donepezil Hydrochloride; Memantine Hydrochloride was by Amneal Pharmaceuticals and was approved on Jan 27, 2017. And the latest generic version is by Ani Pharmaceuticals Inc and was approved on Dec 15, 2023.

Given below is the list of companies who have filed for Donepezil Hydrochloride; Memantine Hydrochloride generic.


1. ANI PHARMS

Ani Pharmaceuticals Inc has filed for 1 generic for Donepezil Hydrochloride; Memantine Hydrochloride. This 10mg;21mg version comes by the name MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Ani Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG; 21MG capsule, extended release Prescription ORAL AB Dec 15, 2023


2. AMNEAL PHARMS

Amneal Pharmaceuticals has filed for 2 different strengths of generic version for Donepezil Hydrochloride; Memantine Hydrochloride. All of these versions come by the name MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Amneal Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
10MG; 14MG capsule, extended release Discontinued ORAL N/A Jan 27, 2017
10MG; 28MG capsule, extended release Discontinued ORAL N/A Jan 27, 2017